What is 21 USC 352? A Complete Guide to Misbranded Drugs and Devices

Table of Contents#

1. What is 21 USC 352?
2. Key Definitions: Drugs, Devices, and Misbranding
3. Criteria for Misbranding Under 21 USC 352
4. Examples of Misbranded Drugs and Devices
5. Consequences of Misbranding
6. FDA Enforcement of 21 USC 352
7. Conclusion
8. References

What is 21 USC 352?#

21 USC 352 is a federal law under Title 21 of the United States Code, which regulates food, drugs, cosmetics, and medical devices. Enacted as part of the FD&C Act of 1938 (and amended over time), its primary purpose is to prevent the distribution of misbranded drugs and devices by setting clear standards for labeling, packaging, and marketing.

In short, 21 USC 352 ensures that consumers receive accurate, truthful, and complete information about the products they use—whether it’s a prescription medication, over-the-counter (OTC) drug, or a medical device like a pacemaker or glucose monitor. By defining what constitutes misbranding, the law empowers the Food and Drug Administration (FDA) to take action against non-compliant products, protecting public health.

Key Definitions: Drugs, Devices, and Misbranding#

To understand 21 USC 352, it’s essential to define the terms it regulates:

1. Drug (as per 21 USC 321(g))#

A "drug" is any substance intended for use in:

• The diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals.
• Affecting the structure or function of the body (e.g., vitamins, supplements, or hormonal treatments).

2. Device (as per 21 USC 321(h))#

A "device" is an instrument, machine, tool, implant, or other article intended for:

• Diagnosing, treating, or preventing disease.
• Affecting the structure or function of the body.
• Without relying on chemical action (unlike drugs). Examples include syringes, surgical gloves, and MRI machines.

3. Misbranding#

Under 21 USC 352, a drug or device is "misbranded" if its labeling (including packaging, inserts, or advertising) is false, misleading, or fails to meet legal requirements. This includes omitting critical information, making unproven claims, or misrepresenting ingredients.

Criteria for Misbranding Under 21 USC 352#

21 USC 352 outlines specific scenarios where a drug or device is considered misbranded. Below are the most common criteria (summarized from the statute’s subsections):

1. False or Misleading Labeling (21 USC 352(a))#

A product is misbranded if its label is "false or misleading in any particular." This includes:

• Exaggerated claims (e.g., "cures diabetes" for an unproven supplement).
• Hiding side effects or risks (e.g., a painkiller failing to mention liver toxicity).
• Misrepresenting the product’s origin (e.g., labeling a foreign-made drug as "Made in the USA").

2. Missing Manufacturer Information (21 USC 352(b))#

The label must include the name and place of business of the manufacturer, packer, or distributor. Omission or falsification of this info (e.g., using a fake address) constitutes misbranding.

3. Inadequate Net Quantity Declaration (21 USC 352(c))#

The label must clearly state the net quantity of contents (e.g., "30 tablets" or "100 mL"). Vague terms like "a few" or "some" are not allowed.

4. Established Name and Ingredient Listing (21 USC 352(e))#

For drugs, the label must bear the established name of the drug and the name and quantity of each active ingredient, including any alcohol, bromides, or other specified substances. Falsely claiming an ingredient or omitting required ingredient information constitutes misbranding. For devices with an established name, the label must display that name prominently.

5. Directions for Use and Warnings (21 USC 352(f))#

Labeling must bear adequate directions for use and adequate warnings against use in conditions or by children where the product may be dangerous to health. Prescription drugs must include directions for use under practitioner supervision. OTC drugs must have clear, consumer-friendly directions to avoid misuse (e.g., a cough syrup failing to specify dosage for children).

6. Misleading Container or Packaging (21 USC 352(i))#

Packaging that is "unfair or deceptive" (e.g., a bottle shaped to look larger than its actual volume) or imitation of another drug is misbranding. Additionally, a drug that is "dangerous to health when used in the dosage or manner prescribed" in its labeling is also misbranded under 352(j).

7. Color Additives (21 USC 352(m))#

Color additives in drugs/devices must be FDA-approved and packaged and labeled in conformity with applicable regulations. Using uncertified colors (e.g., a red dye linked to allergic reactions) is misbranding.

8. Other Violations#

Additional criteria include:

• Prescription drug advertisements must include the established name, quantitative formula, and side effects/contraindications information (21 USC 352(n)).
• Drugs from nonregistered establishments or without required device identifiers are misbranded (21 USC 352(o)).
• Drugs subject to an approved risk evaluation and mitigation strategy (REMS) that fail to comply with strategy requirements are misbranded (21 USC 352(y)).
• Reprocessed single-use devices must bear specific labeling identifying them as reprocessed (21 USC 352(v)).

Examples of Misbranded Drugs and Devices#

To illustrate, here are real-world scenarios that would violate 21 USC 352:

• Example 1: A "Natural" Pain Reliever
  A company sells an OTC pain reliever labeled "100% natural" but includes synthetic ibuprofen (an active ingredient) not listed on the label. This violates 21 USC 352(e) (established name and ingredient listing).

• Example 2: A Medical Device Without Warnings
  A glucose monitor fails to include instructions for calibrating the device, leading to inaccurate blood sugar readings. This violates 21 USC 352(f) (directions for use and warnings).

• Example 3: A Dietary Supplement with False Claims
  A supplement advertises "cures Alzheimer’s" on its label, but no clinical trials support this claim. This violates 21 USC 352(a) (false/misleading labeling).

• Example 4: Expired Drugs Sold to Consumers
  A pharmacy sells expired antibiotics with the original expiration date scratched off. This is misbranding under 21 USC 352(a) (misleading labeling).

Consequences of Misbranding#

Violating 21 USC 352 can lead to severe penalties for manufacturers, distributors, and retailers. These include:

1. Civil Penalties#

• Seizure: The FDA can seize misbranded products, removing them from the market.
• Injunctions: Courts may order companies to stop manufacturing or selling non-compliant products.
• Warning Letters: The FDA issues warning letters requiring companies to correct violations, often within 15–30 days. In FY 2025, CDER warning letters increased by 50% compared to the prior year.

2. Criminal Penalties#

Under 21 USC 333(a), criminal penalties for misbranding violations include:

• First offense: Fines up to $1,000 and imprisonment up to 1 year.
• Repeat offenses or intent to defraud: Fines up to $10,000 and imprisonment up to 3 years.
• Prescription drug marketing violations carry enhanced penalties of up to $250,000 in fines and 10 years imprisonment under 21 USC 333(b).

3. Reputational Harm#

Companies found guilty of misbranding often face public backlash, loss of consumer trust, and damage to their brand. This can lead to decreased sales and long-term financial losses.

FDA Enforcement of 21 USC 352#

The FDA is responsible for enforcing 21 USC 352. Its enforcement process typically involves:

1. Inspections#

FDA inspectors visit manufacturing facilities, pharmacies, and retailers to review labeling, packaging, and marketing materials for compliance.

2. Warning Letters#

If violations are found, the FDA issues a warning letter, giving the company 15–30 days to correct the issue. Failure to comply can lead to further action. In FY 2025, CDER warning letters jumped 50%, and the FDA issued over 200 enforcement letters challenging prescription drug advertising and promotion.

3. Import Alerts#

For misbranded products imported into the U.S., the FDA may issue import alerts, blocking shipments from entering the country.

4. Legal Action#

If warnings are ignored, the FDA may file lawsuits to seize products, impose fines, or seek injunctions. In extreme cases, criminal charges are pursued. The FBI, FDA Office of Criminal Investigations (FDA-OCI), and DEA also investigate misbranding violations.

Conclusion#

21 USC 352 is a cornerstone of public health protection, ensuring that drugs and devices are labeled truthfully and safely. By defining misbranding and outlining strict penalties, it holds manufacturers accountable and empowers consumers to make informed choices.

For industry stakeholders, compliance with 21 USC 352 is not just a legal obligation—it's a commitment to patient safety. For consumers, understanding misbranding helps identify risky products and report violations to the FDA (via MedWatch or 1-800-FDA-1088).

With FDA enforcement on the rise—including a 50% increase in CDER warning letters in FY 2025—understanding and complying with 21 USC 352 has never been more important. Whether you're a healthcare professional, industry stakeholder, or informed consumer, knowing what constitutes misbranding is essential to maintaining trust and integrity in the U.S. drug and device market.

References#

• Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 301 et seq.
• 21 U.S.C. § 352 - Misbranded drugs and devices. FindLaw
• 21 U.S.C. § 333 - Penalties. Cornell Law Institute
• FDA. Device Labeling. https://www.fda.gov/medical-devices/overview-device-regulation/device-labeling
• FDA. General Device Labeling Requirements. https://www.fda.gov/medical-devices/device-labeling/general-device-labeling-requirements
• FDA. Labeling Resources for Human Prescription Drugs. https://www.fda.gov/drugs/laws-acts-and-rules/fdas-labeling-resources-human-prescription-drugs
• FDA. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
• FDA. MedWatch Safety Reporting. https://www.fda.gov/safety/medwatch